Their findings revealed that PD-L1 expression tended to be higher in KRAS wild-type tumors (30%) compared to KRAS-mutant tumors (11%) [20] Similarly, Puccini et al. analyzed the impact of RAS mutations on the tumor immune microenvironment (TIME) and genomic alterations in colorectal cancer patients with microsatellite instability (MSI) or DNA mismatch repair-deficient (dMMR) tumors [21]. The gene discussed is KRAS; the disease is colorectal cancer.